

S2 Table. Baseline characteristics before and after PSM

	Unmatched cohort			Matched cohort		
	Observation (n=69)	Adjuvant chemotherapy (n=149)	ASD	Observation (n=57)	Adjuvant chemotherapy (n=57)	ASD
Sex						
Male	39 (56.5)	68 (45.6)	0.203	31 (54.4)	30 (52.6)	0.035
Female	30 (43.5)	81 (54.4)		26 (45.6)	27 (47.4)	
Age (yr), mean±SD	63.8±9.3	60.9±8.8	0.317	63.3±9.0	63.2±9.2	0.008
ECOG PS at surgery						
0-1	65 (94.2)	143 (96.0)	0.082	56 (98.2)	56 (98.2)	< 0.001
≥2	4 (5.8)	6 (4.0)		1 (1.8)	1 (1.8)	
Tumor extent at the diagnosis						
Resectable	7 (10.1)	15 (10.1)	0.309	6 (10.5)	5 (8.8)	0.079
BRPC	39 (56.5)	103 (69.6)		35 (61.4)	37 (64.9)	
LAPC	23 (33.3)	30 (20.3)		16 (28.1)	15 (26.3)	
Pathological T stage						
ypT0-T2	61 (88.4)	133 (89.3)	0.027	51 (89.5)	50 (87.7)	0.055
ypT3-T4	8 (11.6)	16 (10.7)		6 (10.5)	7 (12.3)	
Pathological N stage						
ypN0	40 (58.0)	85 (57.0)	0.019	33 (57.9)	31 (54.4)	0.071
ypN1-N2	29 (42.0)	64 (43.0)		24 (42.1)	26 (45.6)	
Resection margin status						

Resection margin negative	58 (84.1)	126 (84.6)	0.014	47 (82.5)	46 (80.7)	0.045
Resection margin positive	11 (15.9)	23 (15.4)		10 (17.5)	11 (19.3)	
No. of cycles of neoadjuvant mFOLFIRINOX, mean±SD	8.6±3.5	6.8±2.3	0.620	7.9±2.9	7.8±2.0	0.036
Preoperative CA 19-9 level						
WNL^{a)}	44 (63.8)	96 (64.4)	0.014	36 (63.2)	38 (66.7)	< 0.001
>UNL	25 (36.2)	53 (35.6)		21 (36.8)	19 (33.3)	

Values are presented as number (%) unless otherwise indicated. ASD, absolute standardized difference; BRPC, borderline resectable pancreatic cancer; ECOG PS, Eastern Cooperative Oncology Group performance score; LAPC, locally advanced pancreatic cancer; mFOLFIRINOX, modified fluorouracil, leucovorin, irinotecan and oxaliplatin; PSM, propensity score matched; SD, standard deviation; UNL, upper normal limit; WNL, within normal limits. ^{a)}17 patients (in the observation group of the unmatched cohort), 28 patients (in the adjuvant chemotherapy group of the unmatched cohort), 15 patients (in the observation group of the matched cohort) and 14 patients (in the adjuvant chemotherapy group of the matched cohort) who had missing CA 19-9 levels were included in the within normal limits (WNL) group.